Home›Alpelisib›Alpelisib + Breast Cancer Resistance Protein Bcrp Substrates

Does Alpelisib Interact with Breast Cancer Resistance Protein Bcrp Substrates?

Alpelisib and Breast Cancer Resistance Protein Bcrp Substrates have a major drug interaction according to U.S. FDA drug labeling data. BCRP inhibitors may increase alpelisib concentration, which may increase the risk of toxicities. Avoid use or closely monitor for increased adverse reactions. The mechanism involves bcrp inhibition increases alpelisib concentration. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Alpelisib and Breast Cancer Resistance Protein Bcrp Substrates occurs because bcrp inhibition increases alpelisib concentration. Clinically, this means bcrp inhibitors may increase alpelisib concentration, which may increase the risk of toxicities. avoid use or closely monitor for increased adverse reactions. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.

What To Tell Your Doctor or Pharmacist

If you are taking Alpelisib and your doctor is considering prescribing Breast Cancer Resistance Protein Bcrp Substrates (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Alpelisib(Vijoice)+💊 Breast Cancer Resistance Protein Bcrp Substrates

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
—
Drug B class
—
Source
NLP:alpelisib

What this means in plain English

BCRP inhibitors may increase alpelisib concentration, which may increase the risk of toxicities. Avoid use or closely monitor for increased adverse reactions.

What the FDA label says

"BCRP inhibition increases alpelisib concentration"

📖 Source: NLP:alpelisib

Share this result:XFacebookWhatsAppReddit
Add more drugs
Check Alpelisib and Breast Cancer Resistance Protein Bcrp Substrates against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.